SOURCE: BioNeutral Group, Inc.

December 19, 2013 08:30 ET

BioNeutral Announces U.S. Sales Representation Agreement With ProSell for Industrial Markets

NEWARK, NJ--(Marketwired - Dec 19, 2013) - BioNeutral Group, Inc. (OTCQB: BONU) (OTCBB: BONU) today announced that it has entered into a Partnership Agreement with ProSell Sales Representatives (ProSell), a national sales agency representing products and services of high quality building products and outdoor consumer goods.

The new agreement provides that ProSell will utilize its national sales force to represent our YGIENE™ 206 Sporicide/Sterilant/Disinfectant to industrial, facility maintenance and building trade distributors and their customers seeking microbial remediation of surfaces. ProSell will market BioNeutral's broad portfolio of YGIENE™ and OGIENE™ products.

Kerston Russell, Managing Partner for ProSell commented "ProSell has embraced BioNeutral and, in particular, YGIENE 206 as a superior solution for the distributors and end users within the Industrial markets we call upon. After working with YGIENE™ for a number of months we have determined that YGIENE™ is best positioned, in the markets we serve, by emphasizing and focusing on its mold killing capabilities. As we have intensified our efforts in this direction we have found that YGIENE™ has proven to be an exceptional product with no equal in the market place. By focusing on the mold killing strengths we have begun to see tremendous success in placing the product with some major distributors. As a professional sales organization, the representatives of ProSell have embraced this product and made it our number one product offering. We feel very privileged to be representing BioNeutral and selling the YGIENE™ and OGIENE™ product lines."

"BioNeutral is developing and implementing market specific channel strategies. This partnership will be the focal point of our penetration into the Industrial, construction, facility maintenance and mold remediation marketplace. This strategic agreement will exponentially expand our reach with a well-connected sales organization providing extensive coverage in one of the largest market segments for our BioNeutral products," stated Ray Dunning, Senior Vice President of Sales for BioNeutral Group, Inc. "The ProSell Sales Team regularly calls on 1,200 to 1,500 customers/distributors each and every week. We are very excited to have this group of professionals bringing YGIENE 206 to a marketplace demanding the most effective solution for mold remediation."

About ProSell Sales Representatives

Headquartered in Mundelein, IL, ProSell is a professional sales group with a national reach focused on bringing value added solutions to the facility maintenance, construction and building industries nationwide. The product families that ProSell represents are critical to protecting and maintaining both the interiors and exteriors of all types of facilities, buildings, institutions and structures throughout the United States. Find ProSell online at

About BioNeutral Group, Inc.

Headquartered in Newark, New Jersey, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, YGIENE™ and OGIENE™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the YGIENE™ brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. For more information on BioNeutral, including a listing of company products, leadership and background please visit

Find us on Facebook:

Follow us on Twitter:

Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.

Contact Information

    Mark Lowenthal
    BioNeutral Group, Inc.